1 Min Read
April 27 (Reuters) - Agile Therapeutics Inc:
* Plans to resubmit its New Drug Application for Twirla to U.S. Food and Drug Administration by end of Q2 of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.